In a once weekly injection of exenatide for Drug-Naive Patients with Type 2 Diabetes (DURATION-4) in a 26-week double-blind study they found that exenatide once weekly (EQW) was noninferior to metformin (MET) but not pioglitazone (PIO) and superior to sitagliptin (SITA) with regard to HbA1c reduction at 26 weeks….
Read the Rest

Tags: sitagliptin, pioglitazone, metformin, exenatide, weekly,

Page Information

  • Keywords: diabetes, diabetes newsletter, diabetic newsletter, diabetes, news for diabetics, news for doctors, diabetes in children, diabetes in control, health, blood sugars, diabetes type 1, diabetes type 2, health care, blood sugars, low blood sugars, lower blood sugars, a1cnow, hba1c, hemoglobin a1c, sportbrain, tacticon, diabetes care, pharmacy
  • Description: Diabetes In Control is a free weekly diabetes newsletter dedicated to helping medical professionals in diabetes care better help their diabetes patients.